Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
J Hematol Oncol. 2024 Jun 24;17(1):49. doi: 10.1186/s13045-024-01568-z.
Significant advances have been made in chimeric antigen receptor T (CAR-T)-cell therapy for the treatment of recurrent or refractory B-cell hematologic malignancies. However, CAR-T-cell therapy has not yet achieved comparable success in the management of aggressive T-cell malignancies. This article reviews the challenges of CAR-T-cell therapy in treating T-cell malignancies and summarizes the progress of preclinical and clinical studies in this area. We present an analysis of clinical trials of CAR-T-cell therapies for the treatment of T-cell malignancies grouped by target antigen classification. Moreover, this review focuses on the major challenges encountered by CAR-T-cell therapies, including the nonspecific killing due to T-cell target antigen sharing and contamination with cell products during preparation. This review discusses strategies to overcome these challenges, presenting novel therapeutic approaches that could enhance the efficacy and applicability of CAR-T-cell therapy in the treatment of T-cell malignancies. These ideas and strategies provide important information for future studies to promote the further development and application of CAR-T-cell therapy in this field.
嵌合抗原受体 T（CAR-T）细胞疗法在治疗复发性或难治性 B 细胞血液恶性肿瘤方面取得了重大进展。然而，CAR-T 细胞疗法在治疗侵袭性 T 细胞恶性肿瘤方面尚未取得可比的成功。本文综述了 CAR-T 细胞疗法在治疗 T 细胞恶性肿瘤方面面临的挑战，并总结了这一领域的临床前和临床研究进展。我们对按靶抗原分类的 CAR-T 细胞治疗 T 细胞恶性肿瘤的临床试验进行了分析。此外，本综述重点讨论了 CAR-T 细胞疗法遇到的主要挑战，包括 T 细胞靶抗原共享导致的非特异性杀伤和在制备过程中细胞产物的污染。本综述讨论了克服这些挑战的策略，提出了一些新的治疗方法，这些方法可以提高 CAR-T 细胞疗法在治疗 T 细胞恶性肿瘤中的疗效和适用性。这些想法和策略为未来的研究提供了重要信息，以促进 CAR-T 细胞疗法在该领域的进一步发展和应用。
